A PYMNTS Company

Bain, Cinven Near Deal for $4.4B Lonza Unit

By  |  February 8, 2021

Bain Capital and Cinven agreed to acquire Lonza Group AG’s specialty ingredients unit, bringing to a close one of the most hotly contested sales in European chemicals.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The deal is worth 4.2 billion Swiss francs ($4.7 billion), including debt, according to a statement Monday, confirming a Bloomberg News report. The transaction, scheduled to close in the second half of 2021, will refocus Lonza as a pure-play partner to the health-care industry, and the cash flow from the sale will accelerate its strategic priorities, the company said.

    “Today’s announcement is the result of a comprehensive and robust selection process,” Lonza Chairman Albert M. Baehny said in a statement. “Bain Capital and Cinven have shown they understand the value of the experience and expertise of our specialty ingredients employees. They presented the most compelling industrial strategy and vision for the business.”

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.